• Explore /
  • Poster
  • / Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial.

Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial.

Abstract Poster

Authors

Manisha Shah

Manisha Shah

Ohio State University Comprehensive Cancer Center

Manisha Shah , Catherine Lombard-Bohas , Tetsuhide Ito , Edward Wolin , Eric Van Cutsem , Carolin Sachs , Robert Winkler , Jeremie Lincy , Timothy Hobday , James Yao

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2011 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Other GI Cancer

Clinical Trial Registration Number

NCT00510068

Citation

J Clin Oncol 29: 2011 (suppl; abstr 4010)

Abstract #

4010

Poster Bd #

3

Abstract Disclosures

Similar Posters

First Author: Jonathan Strosberg

First Author: Marianne E. Pavel

First Author: Elisabeth De Vries

First Author: Lowell Anthony